OncoSec Medical (OTCPK:ONCS.Q) - Aktienkurs, Nachrichten und Analyse

ONCS.Q Aktienübersicht

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. Mehr Details

ONCS.Q grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	0/6
Dividenden	0/6

Risikoanalyse

Hat keine nennenswerte Marktkapitalisierung ($805K)

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Negatives Eigenkapital

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

+ 3 mehr Risiken

OncoSec Medical Incorporated Wettbewerber

SQZ Biotechnologies

OTCPK:SQZB

US$737.3k

Bellerophon Therapeutics

OTCPK:BLPH

US$672.8k

Vyant Bio

OTCPK:VYNT

US$1.1m

ZyVersa Therapeutics

NasdaqCM:ZVSA

US$2.5m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für OncoSec Medical
Historische Aktienkurse
Aktueller Aktienkurs	US$0.13
52-Wochen-Hoch	US$18.99
52-Wochen-Tief	US$0.11
Beta	2
11 Monat Veränderung	-68.98%
3 Monate Veränderung	-94.83%
1 Jahr Veränderung	-99.25%
33 Jahre Veränderung	-99.70%
5 Jahre Veränderung	-99.95%
Veränderung seit IPO	-98.61%

Aktuelle Nachrichten und Updates

Recent updates

OncoSec to cut workforce by 45% as part of corporate restructuring

Oct 04

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

Jan 28

Dosing underway in OncoSec's Tavo combo trial in skin cancer

Jan 08

OncoSec: Undervalued And Continuing To Make Progress

Nov 18

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

Nov 09

Aktionärsrenditen

	ONCS.Q	US Biotechs	US Markt
7D	-36.5%	2.5%	1.0%
1Y	-99.3%	15.6%	31.4%

Rendite im Vergleich zur Industrie: ONCS.Q unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 15.6% erzielte.

Rendite vs. Markt: ONCS.Q hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 31.4 erzielte.

Preisvolatilität

Is ONCS.Q's price volatile compared to industry and market?
ONCS.Q volatility
ONCS.Q Average Weekly Movement	28.4%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: ONCS.QDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: ONCS.QDie wöchentliche Volatilität (28%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2008	41	n/a	oncosec.com

OncoSec Medical Incorporated's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von OncoSec Medical im Vergleich zum Marktanteil des Unternehmens?
ONCS.Q grundlegende Statistiken
Marktanteil	US$804.96k
Gewinn(TTM)	-US$29.39m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

0.0x

Kurs-Gewinn-Verhältnis

Ist ONCS.Q zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ONCS.Q Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$29.39m
Umsatz	-US$29.39m

Zuletzt gemeldete Gewinne

Jan 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-4.93
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	-132.9%

Wie hat sich ONCS.Q auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ONCS.Q Aktienübersicht

Risikoanalyse

OncoSec Medical Incorporated Wettbewerber

OTCPK:SQZB

US$737.3k

OTCPK:BLPH

US$672.8k

OTCPK:VYNT

US$1.1m

NasdaqCM:ZVSA

US$2.5m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.

Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program

High number of new directors

OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC

Recent updates

OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.

Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program

High number of new directors

OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated Presents Encouraging Early Data with TAVO™-EP combined with Nivolumab (Opdivo®) in Neoadjuvant Melanoma

Oncosec Medical Incorporated Announces Positive Clinical Data of the Keynote-695 Trial Assessing Tavo-Ep in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to Anti-Pd-1 Treatment

OncoSec Medical Incorporated Elects Robert H. Arch as Non-Independent Director of the Board

OncoSec Medical Incorporated Elects Stephany Foster as an Independent Director

OncoSec Medical Incorporated Announces Workforce Reduction

OncoSec to cut workforce by 45% as part of corporate restructuring

OncoSec Medical Incorporated Appoints Joon Kim to the Audit Committee

OncoSec Medical Incorporated, Annual General Meeting, Nov 23, 2022

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated Appoints Robert H. Arch as Chief Executive Officer

Price target decreased to US$5.00

Less than half of directors are independent

OncoSec Medical Incorporated, Annual General Meeting, Jul 12, 2022

Price target decreased to US$5.00

OncoSec Medical Incorporated Announces Appointment of George Chi as Chief Financial Officer

Oncosec Medical Receives Notice from the Nasdaq Stock Market

Less than half of directors are independent

Interim CEO & COO Brian Leuthner has left the company

Forecast to breakeven in 2024

President, CEO & Director Daniel O'Connor has left the company

OncoSec Medical Incorporated, Annual General Meeting, Apr 29, 2021

Price target raised to US$8.13

OncoSec Medical Incorporated Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, Tavo™, in Triple Negative Breast Cancer

OncoSec Medical Incorporated Appoints Bridget O'keeffe as Vice President of Clinical Development

OncoSec Medical Incorporated Announces Management Appointments

New 90-day high: US$7.71

OncoSec Announces First Subjects Dosed in Phase 1 Trial of Corvax12, Oncosec's Covid-19 Vaccine Candidate Combining Interleukin-12 (Il-12) with an Enhanced Sars-Cov-2 Spike Protein

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $42.026498 million.

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

New 90-day high: US$6.81

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

Dosing underway in OncoSec's Tavo combo trial in skin cancer

New 90-day high: US$6.65

OncoSec Medical Incorporated Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO and its Gene Electrotransfer Technology

OncoSec Medical Incorporated Announces Exclusive License Agreement for Cliniporator Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

OncoSec: Undervalued And Continuing To Make Progress

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

New 90-day high: US$5.11

OncoSec Medical Incorporated to Present Positive Interim Data from Keynote-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19

OncoSec Medical Incorporated Announces Stepping Down of Kellie Malloy Foerter as Chief Operating Officer

OncoSec Medical Incorporated Announces Appointment of Sandra Aung as Senior Vice President, Chief Clinical Development Officer

OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO and Its Gene Delivery Platform

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $14.977914 million.

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

OncoSec Medical Incorporated's Grundlagenzusammenfassung

0.0x

0.0x

Erträge & Einnahmen